Fig. 2: The chimeric transcript level of the CBF-AML patients after induction therapy. | Blood Cancer Journal

Fig. 2: The chimeric transcript level of the CBF-AML patients after induction therapy.

From: Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients

Fig. 2

A The chimeric transcript level of all CBFB::MYH11 patients. B, C The chimeric transcript level of CBFB::MYH11 cohort with or without FLT3-ITD/NRAS/KIT mutation. D The chimeric transcript level of all patients with RUNX1::RUNX1T1. E, F The chimeric transcript level of RUNX1::RUNX1T1 cohort with or without FLT3-ITD/NRAS/KIT mutation.

Back to article page